Roche and Trimeris apply for FDA approval of Fuzeon
BY Advocate.com Editors
September 19 2002 12:00 AM ET
Drugmakers Roche and Trimeris on Tuesday applied to the Food and Drug Administration for approval of their new anti-HIV drug Fuzeon, formerly known as T-20, The Wall Street Journal reports. The companies requested a priority six-month review for the compound and hope to have it on the market in the first quarter of 2003. Fuzeon is the drug in a new class of medications called entry or fusion inhibitors, which work outside the body's cells by preventing HIV from attaching to and infecting them. The FDA application requested review for Fuzeon as part of combination therapy to treat HIV infection.
Roche and Trimeris officials say the drug is designed to treat patients whose HIV has become resistant to other antiretroviral drugs. The companies plan to file for European Union approval of the drug by the end of the month. Analysts say that a year's supply of the drug, which must be
injected, will cost between $10,000 and $15,000.
Sign Up For Email Updates
- Crime Does Expansion of Rights Also Expand Antigay Violence? 21 min 50 sec ago
- Film New Man Of Steel and Wolverine Trailers Debut 2 hours 25 min ago
- Travel Top 10 Ways to Score and Upgrade on Your Next Flight 8:27 AM
- Travel A Perfect Day in Rio 7:59 AM
- Marriage Equality Recalls of Pro-Marriage Equality Lawmakers Quashed in Minnesota 5:30 AM
- Commentary Op-ed: My Life as a Gay Boy Scout 4:34 AM
- Current Issue A Reason for Pride: Gay Parents Are Changing the World 4:00 AM